Want to see GB:OBI full AI Analyst Report?
Total Valuation
Ondine Biomedical, Inc. has a market cap or net worth of £76.46M. The enterprise value is 109.78M .
Market Cap£76.46M
Enterprise Value109.78M
Share Statistics
Ondine Biomedical, Inc. has 518,366,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding518,366,940
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ondine Biomedical, Inc.’s return on equity (ROE) is -8.48 and return on invested capital (ROIC) is -769.72%.
Return on Equity (ROE)-8.48
Return on Assets (ROA)-2.06
Return on Invested Capital (ROIC)-769.72%
Return on Capital Employed (ROCE)-8.37
Revenue Per Employee147.36K
Profits Per Employee-1.64M
Employee Count18
Asset Turnover0.18
Inventory Turnover0.86
Valuation Ratios
The current PE Ratio of Ondine Biomedical, Inc. is ―. Ondine Biomedical, Inc.’s PEG ratio is 0.28.
PE Ratio―
PS Ratio28.32
PB Ratio21.53
Price to Fair Value21.53
Price to FCF-3.13
Price to Operating Cash Flow-5.64
PEG Ratio0.28
Income Statement
In the last 12 months, Ondine Biomedical, Inc. had revenue of 2.65M and earned -29.59M in profits. Earnings per share was -0.06.
Revenue2.65M
Gross Profit1.09M
Operating Income-30.04M
Pretax Income-29.59M
Net Income-29.59M
EBITDA-29.45M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -23.89M and capital expenditures -116.79K, giving a free cash flow of -24.01M billion.
Operating Cash Flow-23.89M
Free Cash Flow-24.01M
Free Cash Flow per Share-0.05
Dividends & Yields
Ondine Biomedical, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change3.51%
50-Day Moving Average13.75
200-Day Moving Average11.72
Relative Strength Index (RSI)61.83
Average Volume (3m)160.07K
Important Dates
Ondine Biomedical, Inc. upcoming earnings date is Sep 30, 2026, Before Open (Confirmed).
Last Earnings DateJun 4, 2026
Next Earnings DateSep 30, 2026
Ex-Dividend Date―
Financial Position
Ondine Biomedical, Inc. as a current ratio of 1.23, with Debt / Equity ratio of 11.85%
Current Ratio1.23
Quick Ratio1.06
Debt to Market Cap<0.01
Net Debt to EBITDA0.35
Interest Coverage Ratio-1.43K
Taxes
In the past 12 months, Ondine Biomedical, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Ondine Biomedical, Inc. EV to EBITDA ratio is -2.21, with an EV/FCF ratio of -2.70.
EV to Sales24.49
EV to EBITDA-2.21
EV to Free Cash Flow-2.70
EV to Operating Cash Flow-2.72
Balance Sheet
Ondine Biomedical, Inc. has £10.58M in cash and marketable securities with £413.50K in debt, giving a net cash position of £10.17M billion.
Cash & Marketable Securities£10.58M
Total Debt£413.50K
Net Cash£10.17M
Net Cash Per Share£0.02
Tangible Book Value Per Share<£0.01
Margins
Gross margin is 41.14%, with operating margin of -1132.54%, and net profit margin of -1115.53%.
Gross Margin41.14%
Operating Margin-1132.54%
Pretax Margin-1115.53%
Net Profit Margin-1115.53%
EBITDA Margin-1110.24%
EBIT Margin-1132.54%
Analyst Forecast
The average price target for Ondine Biomedical, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast22.87%
EPS Growth Forecast13.35%